This working paper aims to synthesise existing research and thinking on how antimicrobials are procured and ways to improve the current purchasing system.

This note takes a quick look at the lessons learned and the existing landscape of MCM manufacturing in the context of the current pandemic response and suggests eight areas for action along with near-term recommendations to the global community to both prepare and respond to future pandemic risks. 

While oral antivirals are not a substitute for vaccination, they are key to preventing severe illness, saving lives, and preserving health systems. Vaccination rates continue to be low in low-income countries; only 14 percent of the population in low-income countries has received one dose of the vac...

The COVID-19 pandemic has transformed the global vaccine manufacturing landscape, with capacity more than doubling in the past 18 months. Before the pandemic, manufacturers produced an estimated total of five billion vaccine doses each year. In 2021, manufacturers produced 12 billion doses of C...

India lacks an authoritative estimate of the death toll from the COVID-19 pandemic. We report excess mortality estimates from three different data sources from the pandemic’s start through June 2021. Estimating COVID-deaths with statistical confidence may prove elusive. But all estimates suggest tha...

The central fact that has motivated the empirics of economic growth—namely unconditional divergence—is no longer true and has not been so for decades.

The IMF’s forecasts of GDP growth in 2020 suggest a substantially muted impact of the COVID crisis for developing countries compared to advanced economies. We hope that the relative optimism will not induce complacency and elicit a less-than-forceful response by countries themselves nor legitim...